Figure 2 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9

Authors: Paul L. Swiecicki, Glenn J. Hanna, Jessica L. Geiger et al.

Publication:

Published: Unknown date

Source: Crossref

Back to Search View Original Cite This Article

Abstract

<jats:p>Efficacy per investigator assessment. A, Best change from baseline in the size of the target lesion. B, Time to response and DOR in patients with confirmed responses. C, Kaplan–Meier plots of PFS. N/A, not applicable; PD, progressive disease; SD, stable disease.</jats:p>

Keywords

pefficacy investigator assessment best change

Figure 2 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9

Abstract

Keywords

Related Articles

The Application of Interactive Digital Media Reviewed From the Cognitive Abilietes of Early Childhood Education Students Aged 4-5 Years

Data from Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors

Supplementary Table S4 from &lt;i&gt;Fusobacterium nucleatum&lt;/i&gt; Promotes Exosomal LncRNA &lt;i&gt;MANCR&lt;/i&gt; Secretion from Colorectal Cancer Cells to Induce PD-L1 Expression in Macrophages

Supplementary Figure S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial

Supplementary Video S6 from Autophagy Inhibition Reprograms the Tumor Microenvironment of Pancreatic Cancer to Promote Macrophage Phagocytosis of Tumor Cells

Supplementary Table S4 from <i>Fusobacterium nucleatum</i> Promotes Exosomal LncRNA <i>MANCR</i> Secretion from Colorectal Cancer Cells to Induce PD-L1 Expression in Macrophages